New TB vaccine aims to prevent active lung disease in adults

NCT ID NCT04975737

Ongoing ⭐️ VACCINE ⭐️ Sponsor: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This Phase 3 trial tests the GamTBvac vaccine to prevent active pulmonary tuberculosis in adults aged 18 and older. The study includes people with and without a prior history of TB, comparing the vaccine to a placebo. Researchers will monitor how many participants develop active TB over two years, as well as any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GamTBvac tuberculosis vaccine
What this could lead to: If successful, this vaccine could help prevent active tuberculosis in adults, reducing the global burden of this serious lung infection.
What could go wrong: This is a large Phase 3 trial, but vaccines can fail to show sufficient protection. Safety and long-term efficacy are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY TUBERCULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary tuberculosis tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TUBERCULOSIS

Contacts and locations

Show contact details

Locations

City hospital #40

Saint Petersburg, 197706, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.